Weijian Pharma to Market Infertility Drug in China for LG Lifesciences

China's Weijian Pharma Group obtained China marketing rights to an infertility treatment produced by LG Lifesciences of Korea. The treatment is Follitrope, an ovulation induction product, which increases follicle stimulating hormone (FSH). LG Lifesciences  developed Follitrope using its own recombinant DNA methods. Headquartered in Hong Kong, Weijian offers a large portfolio of products to China's market. Terms of the agreement were not disclosed. More details.... Share this with colleagues: // //